Our study highlights key molecular and immune differences across R/M SCCHN subgroups, identifies potential biomarkers, and suggests biological rationales for tailored therapeutic strategies.
Molecular and immune landscape of recurrent and/or distant metastatic squamous cell carcinoma of the head and neck: an EORTC/IMMUCAN project
A. van der Elst·Jean-Pascal Machiels·Lucas Michon·M. Morfouace·Robin Liechti·P Devanand·D. Schulz·Maya Persoons·Sylvie Rusakiewicz·Nils Eling·Paul-Antoine Nicolas·Marie-Sophie Robert·Stephanie Tissot·Sophie Déglise·Bruno Palau Fernandez·Bernd Bodenmiller·Henoch S. Hong·R. Galot·Paolo Bossi·Júlio Oliveira·M. Pracht·Caroline Even·Pierre Saintigny·Céline Lefebvre·Loredana Martignetti·Daniel Herrero-Saboya